Posts

Posted on

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

New human pharmacokinetic (PK) and other pre-clinical data supports use of RenovoRx’s novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting.

The abstract, titled “Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial,” is co-authored by Dr. Ramtin Agah, RenovoRx’s Chief Medical Officer. The abstract supports RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform via additional human PK data and pre-clinical data.

TAMP is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to locoregional treatment offers the potential for increased safety, tolerance, and improved efficacy.

RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial is evaluating the Company’s novel investigational drug-device combination product candidate, (intra-arterial delivery of gemcitabine via RenovoCath) known as IAG, utilizing the TAMP drug delivery platform in patients with Locally Advanced Pancreatic Cancer (LAPC). RenovoRx currently anticipates the completion of both patient enrollment and the second interim analysis for TIGeR-PaC in mid-2025. This abstract is a sub-study of the TIGeR-PaC clinical trial. The combination product candidate (IAG), which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and has not been approved for commercial sale.

SSO 2025 Abstract Details:

  • Title: Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial
  • Authors: Emmanuel Zervos MD, Paula Novelli MD, Amer Zureikat MD, Michael Pishvaian MD, Kenneth Meredith MD, Hassan Hatoum MD, Reza Nazemzadeh MD, Sandeep Loria MD, Ramtin Agah MD
  • Location: ePoster P379 at Tampa Convention Center, Tampa, FL
  • Dates: March 27 – 29, 2025

About RenovoCath

Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-F-Universal-IFU.pdf.

About the TIGeR-PaC Clinical Trial

TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of LAPC. RenovoRx’s first investigational drug-device combination product candidate (intra-arterial delivery of gemcitabine via RenovoCath, known as IAG) using the TAMP therapy platform enabled with the Company’s FDA-cleared RenovoCath® device for the intra-arterial administration of chemotherapy, gemcitabine.

The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study’s primary endpoint is an overall survival benefit with secondary endpoints including reduced side effects versus standard of care. The second interim analysis for this study will be triggered by the 52nd event (i.e., patient death), which is estimated to occur in the second quarter of 2025. The second interim data readout would follow thereafter, with the timing for such readout depending on customary factors such as time needed for analysis. RenovoRx is also aiming to complete patient enrollment in the TIGeR-PaC study in mid-2025.

About RenovoRx, Inc.

RenovoRx is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

In addition to the RenovoCath device, RenovoRx is also evaluating our novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). IAG is being evaluated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. The investigational IAG utilizes RenovoCath, the Company’s FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The intra-arterial infusion of chemotherapy, gemcitabine, utilizing the RenovoCath device is currently being evaluated for the treatment of LAPC by the Center for Drug Evaluation and Research (the drug division of FDA).

IAG by the RenovoCath catheter is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years of market exclusivity upon new drug application approval by the FDA.

RenovoRx is also engaged in implementing commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath device as stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, certain of these customers have already initiated repeat orders as RenovoRx works to expand the number medical institutions that have initiated the process for RenovoCath purchase orders, including several esteemed, high volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity either on its own or in tandem with a medical device commercial partner.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our pre-clinical and clinical trials and studies, including the overall timing and timing for additional interim data readouts for our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential of RenovoCath® or TAMP™ as standalone commercial products, our anticipated timing for revenue generation from RenovoCath sales, and our commercialization plans in general, (iii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iv) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, commercial plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our execution of our commercial strategy for RenovoCath or our TAMP technology may not lead to viable or repeating revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of TIGeR-PaC and any other preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T:212-896-1254

[email protected]

KEYWORDS: United States North America California Florida

INDUSTRY KEYWORDS: Research Surgery FDA Clinical Trials Health Pharmaceutical General Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Corporacion America Airports Reports Fourth Quarter and Full Year 2024 Results

Corporacion America Airports Reports Fourth Quarter and Full Year 2024 Results

Solid results with Adjusted EBITDA margin expansion in all geographies mitigated soft performance in Argentina

Passenger traffic in Argentina rebounded to record-highs in Dec ’24 and Jan ‘25

Cash & Cash Equivalents at $440 million with Net Debt to LTM Adjusted EBITDA of 1.1x

LUXEMBOURG–(BUSINESS WIRE)–Corporación América Airports S.A. (NYSE: CAAP), (“CAAP” or the “Company”) one of the leading private airport operators in the world, reported today its unaudited, consolidated results for the three-month period ended December 31, 2024, and audited results for the full year 2024. Financial results are expressed in millions of U.S. dollars and are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (“IASB”).

Commencing 3Q18, the Company began reporting results of its Argentinean subsidiaries applying Hyperinflation Accounting, in accordance with IFRS rule IAS 29 (“IAS 29”), as detailed in Section“Hyperinflation Accounting in Argentina” on page 23.

Fourth Quarter 2024 Highlights

  • Consolidated Revenues ex-IFRIC12 totaled $396.2 million, up 23.1% year-over-year (YoY), driven by increases of 29.0% and 17.5% in Aeronautical Revenues and Commercial Revenues, respectively. Excluding rule IAS 29, consolidated revenues ex-IFRIC12 decreased 0.6% YoY to $395.2 million.
  • Key operating metrics:

    • 1.2% decrease in passenger traffic to 20.5 million, but up 1.5% when excluding Natal.
    • 16.3% increase in cargo volume to 118.2 thousand tons.
    • 1.9% increase in aircraft movements, or 4.3% when excluding Natal.
  • Operating Income of $108.4 million, compared with $263.6 million in 4Q23 which included a $62.7 million portion of the $166.5 million EBITDA contribution from the indemnification payment received in connection with the friendly termination of the Natal airport concession agreement in Brazil.
  • Adjusted EBITDA ex-IFRIC12 decreased 49.5% to $150.8 million, from $298.8 million in the year-ago period. Excluding the impact of rule IAS 29 and the aforementioned Natal-related contribution recorded in 4Q23, Adjusted EBITDA ex-IFRIC12 decreased 6.7% to $150.5 million.
  • Adjusted EBITDA margin ex-IFRIC12 was 38.0% compared to 92.9% in 4Q23. Adjusting for both rule IAS 29 and the Natal-related impact in 4Q23, Adjusted EBITDA margin ex-IFRIC12 contracted to 38.1% from 40.5% in the prior-year quarter.
  • Strong liquidity position with Cash & Cash equivalents of $439.8 million as of December 31, 2024.
  • Net debt to LTM Adjusted EBITDA improved to 1.1x as of December 31, 2024, from 1.4x as of December 31, 2023.

Full Year 2024 Highlights

  • Consolidated Revenues ex-IFRIC12 increased 29.0% year-over-year (YoY) to $1,619.9 million, reflecting increases of 36.0% and 22.4% in Aeronautical Revenues and Commercial Revenues, respectively. Excluding rule IAS 29, consolidated revenues ex-IFRIC12 decreased 0.4% YoY to $1,534.6 million.
  • Key operating metrics:

    • 2.7% decrease in passenger traffic to 79.0 million, or 0.4% lower when excluding Natal.
    • 7.5% increase in cargo volume to 398.0 thousand tons.
    • 3.0% decrease in aircraft movements, or 1.3% lower when excluding Natal.
  • Operating Income of $447.3 million, compared to $540.6 million in 2023. Operating income in 2023 included a $62.7 million portion of the $166.5 million EBITDA contribution from the indemnification payment received in connection with the friendly termination of the Natal airport concession agreement in Brazil.
  • Adjusted EBITDA ex-IFRIC12 decreased 7.3% to $622.2 million, from $671.3 million in 2023. Excluding rule IAS 29 and the aforementioned Natal-related contribution recorded in 4Q23, Adjusted EBITDA ex-IFRIC12 decreased 8.5% to $581.5 million.
  • Adjusted EBITDA margin ex-IFRIC12 of 38.4% compared to 53.5% in 2023. Adjusting for both rule IAS 29 and the Natal contribution in 4Q23, Adjusted EBITDA margin ex-IFRIC12 contracted to 37.9% from 41.2% in 2023.
  • Strong liquidity position with Cash & Cash equivalents totaling $439.8 million as of December 31, 2024.
  • Net debt to LTM Adjusted EBITDA improved to 1.1x as of December 31, 2024, from 1.4x as of December 31, 2023.

CEO Message

Commenting on the results for the quarter Mr. Martín Eurnekian, CEO of Corporación América Airports, noted: “Our fourth-quarter results reflect, once again, the strength of our diversified portfolio, which continues to support our solid performance despite the challenges we faced in Argentina. While total passenger traffic declined slightly in the quarter, we were encouraged by a notable rebound in domestic traffic in Argentina toward year-end, culminating in record-high passenger volumes in December. This positive momentum extended into the first months of 2025. International passenger traffic in Argentina performed particularly well during the quarter, increasing by more than 11% year-over-year and driving hard-currency revenue streams. This encouraging trend, combined with solid contributions from our operations in Italy, Uruguay, and Brazil, underscores the strength of our geographically diverse portfolio.

On the financial front, consolidated 4Q24 comparisons were affected by the sharp devaluation of the Argentine peso in December 2023 and the indemnification payment received in 4Q23, in connection with Natal termination. The latter also impacted comparability in the Brazil segment. Excluding these factors, revenues declined 0.6%, in line with lower passenger volumes. By contrast, revenue per passenger improved slightly, reflecting our focus on efficiency and commercial revenue growth. Importantly, all regions except Argentina, delivered positive year-over-year Adjusted EBITDA contributions, helping mitigate softness in the Argentine market, which has already shown signs of improvement in the first two months of 2025.

We are advancing key initiatives to enhance the passenger experience and drive commercial revenue growth across our network. In Argentina, we are expanding Ezeiza Airport’s duty-free arrivals area by over 50% to 1,100 square meters. In Uruguay, we inaugurated a new state-of-the art private aviation terminal at Punta del Este Airport, and the construction of a new covered parking facility at Montevideo Airport is progressing as planned. We are also advancing development projects in Armenia and Italy and remain active in exploring opportunities that align with our long-term growth strategy.

In conclusion, we remain committed to advancing our strategic growth plans while building on the strong results achieved throughout 2024. With a solid balance sheet and a net leverage ratio of 1.1x, we are well-positioned to support our growth initiatives while remaining committed to delivering long-term value for our shareholders.”

Operating & Financial Highlights

(In millions of U.S. dollars, unless otherwise noted)

 

4Q24 as reported

4Q23 as reported

% Var as reported

IAS 29 4Q24

4Q24 ex IAS 29

4Q23 ex IAS 29

% Var ex IAS 29

Passenger Traffic (Million Passengers)

20.5

20.7

-1.2%

 

20.5

20.7

-1.2%

Revenue

461.1

365.0

26.3%

-0.6

461.6

454.6

1.5%

Aeronautical Revenues

211.6

164.0

29.0%

-1.1

212.7

209.1

1.7%

Non-Aeronautical Revenues

249.5

201.0

24.1%

0.6

248.9

245.5

1.4%

Revenue excluding construction service

396.2

321.8

23.1%

1.1

395.2

397.6

-0.6%

Operating Income / (Loss)

108.4

263.6

-58.9%

-26.3

134.7

305.1

-55.9%

Operating Margin

23.5%

72.2%

-4,869

0.0%

29.2%

67.1%

-3,793

Net (Loss) / Income Attributable to

Owners of the Parent

34.4

130.7

-73.7%

13.1

21.3

34.9

-38.9%

Basic EPS (US$)

0.21

0.81

-73.6%

0.08

0.13

0.22

-39.0%

Adjusted EBITDA

155.4

303.4

-48.8%

0.3

155.1

332.3

-53.3%

Adjusted EBITDA Margin

33.7%

83.1%

-4940

–

33.6%

73.1%

-3,948

Adjusted EBITDA Margin excluding Construction Service

38.0%

92.9%

-5481

–

38.1%

82.4%

-4,435

Net Debt to LTM Adjusted EBITDA

1.1x

1.4x

–

–

–

–

–

Net Debt to LTM Adjusted EBITDA excl.

impairment on intangible assets (1)

1.1x

1.7x

–

–

–

–

–

Note: Figures in historical dollars (excluding IAS29) are included for comparison purposes.

1) LTM Adjusted EBITDA excluding impairments of intangible assets.

Operating & Financial Highlights

(In millions of U.S. dollars, unless otherwise noted)

 

2024 as reported

2023 as reported

% Var as reported

IAS 29 2024

2024 ex

IAS 29

2023 ex

IAS 29

% Var ex IAS 29

Passenger Traffic (Million Passengers)

79.0

81.1

-2.7%

 

79.0

81.1

-2.7%

Revenue

1,843.3

1,400.0

31.7%

94.0

1,749.2

1,741.5

0.4%

Aeronautical Revenues

876.7

644.5

36.0%

47.8

828.9

803.6

3.1%

Non-Aeronautical Revenues

966.5

755.6

27.9%

46.2

920.3

937.8

-1.9%

Revenue excluding construction service

1,619.9

1,255.3

29.0%

85.3

1,534.6

1,541.0

-0.4%

Operating Income / (Loss)

447.3

540.6

-17.3%

-59.3

506.5

707.0

-28.4%

Operating Margin

24.3%

38.6%

-1,435

–

29.0%

40.6%

-1164

Net (Loss) / Income Attributable to

Owners of the Parent

282.7

239.5

18.0%

68.6

214.0

126.5

69.2%

Basic EPS (US$)

1.76

1.49

17.9%

0.43

1.33

0.79

69.0%

Adjusted EBITDA

628.7

677.7

-7.2%

40.7

588.0

808.4

-27.3%

Adjusted EBITDA Margin

34.1%

48.4%

-1,430

–

33.6%

46.4%

-1,280

Adjusted EBITDA Margin excluding

Construction Service

38.4%

53.5%

-1506

–

37.9%

52.0%

-1,414

Net Debt to LTM Adjusted EBITDA

1.1x

1.4x

–

–

–

–

–

Net Debt to LTM Adjusted EBITDA excl.

impairment on intangible assets (1)

1.1x

1.7x

–

–

–

–

–

Note: Figures in historical dollars (excluding IAS29) are included for comparison purposes.

1) LTM Adjusted EBITDA excluding impairments of intangible assets.

To obtain the full text of this earnings release and the earnings presentation, please click on the following link: http://investors.corporacionamericaairports.com/Results-Center

4Q24 EARNINGS CONFERENCE CALL

When: 09:00 a.m. Eastern Time, March 19, 2025

Who:

Mr. Martín Eurnekian, Chief Executive Officer

Mr. Jorge Arruda, Chief Financial Officer

Mr. Patricio Iñaki Esnaola, Head of Investor Relations

Dial-in:

1-800-549-8228 (North America, Toll Free); 1-289-819-1520 (Other locations); Conference ID: 69248

Webcast:

CAAP 4Q24 Earnings Conference Call

Replay:

1-888-660-6264 (North America, Toll Free); 1-289-819-1325 (Other locations); Playback Passcode: 69248 #

Use of Non-IFRS Financial Measures

This announcement includes certain references to Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted EBITDA excluding Construction Service and Adjusted EBITDA Margin excluding Construction service, as well as Net Debt:

Adjusted EBITDA is defined as income for the period before financial income, financial loss, income tax expense, depreciation and amortization.

Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by total revenues.

Adjusted EBITDA excluding Construction Service (“Adjusted EBITDA ex-IFRIC”) is defined as income for the period before construction services revenue and cost, financial income, financial loss, income tax expense, depreciation and amortization.

Adjusted EBITDA Margin excluding Construction Service (“Adjusted EBITDA Margin ex-IFRIC12”) excludes the effect of IFRIC 12 with respect to the construction or improvements to assets under the concession and is calculated by dividing Adjusted EBITDA excluding Construction Service revenue and cost, by total revenues less Construction service revenue.

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted EBITDA excluding Construction Service and Adjusted EBITDA Margin excluding Construction Service are not measures recognized under IFRS and should not be considered as an alternative to, or more meaningful than, consolidated net income for the year as determined in accordance with IFRS or as indicators of our operating performance from continuing operations. Accordingly, readers are cautioned not to place undue reliance on this information and should note that these measures as calculated by the Company, may differ materially from similarly titled measures reported by other companies. We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA excluding Construction Service enhances an investor’s understanding of our performance and are useful for investors to assess our operating performance by excluding certain items that we believe are not representative of our core business. In addition, Adjusted EBITDA and Adjusted EBITDA excluding Construction Service are useful because they allow us to more effectively evaluate our operating performance and compare the results of our operations from period to period without regard to our financing methods, capital structure or income taxes and construction services (when applicable).

Net debt is calculated by deducting “Cash and cash equivalents” from total financial debt.

Figures ex-IAS 29 result from dividing nominal Argentine pesos for the Argentine Segment, by the average foreign exchange rate of the Argentine Peso against the US dollar in the period. Percentage variations ex-IAS 29 figures compare results as presented in the prior year quarter before IAS 29 came into effect, against ex-IAS 29 results for this quarter as described above. For comparison purposes, the impact of adopting IAS 29 in Aeropuertos Argentina 2000, the Company’s largest subsidiary in Argentina, is presented separately in each of the applicable sections of this earnings release, in a column denominated “IAS 29”. The impact from “Hyperinflation Accounting in Argentina” is described in more detail page 23 of this report.

Definitions and Concepts

Commercial Revenues: CAAP derives commercial revenue principally from fees resulting from warehouse usage (which includes cargo storage, stowage and warehouse services and related international cargo services), services and retail stores, duty free shops, car parking facilities, catering, hangar services, food and beverage services, retail stores, including royalties collected from retailers’ revenue, and rent of space, advertising, fuel, airport counters, VIP lounges and fees collected from other miscellaneous sources, such as telecommunications, car rentals and passenger services.

Construction Service revenue and cost: Investments related to improvements and upgrades to be performed in connection with concession agreements are treated under the intangible asset model established by IFRIC 12. As a result, all expenditures associated with investments required by the concession agreements are treated as revenue generating activities given that they ultimately provide future benefits, and subsequent improvements and upgrades made to the concession are recognized as intangible assets based on the principles of IFRIC 12. The revenue and expense are recognized as profit or loss when the expenditures are performed. The cost for such additions and improvements to concession assets is based on actual costs incurred by CAAP in the execution of the additions or improvements, considering the investment requirements in the concession agreements. Through bidding processes, the Company contracts third parties to carry out such construction or improvement services. The amount of revenues for these services is equal to the amount of costs incurred plus a reasonable margin, which is estimated at an average of 3.0% to 5.0%.

About Corporación América Airports

Corporación América Airports acquires, develops and operates airport concessions. Currently, the Company operates 52 airports in 6 countries across Latin America and Europe (Argentina, Brazil, Uruguay, Ecuador, Armenia and Italy). In 2024, Corporación América Airports served 79.0 million passengers, 2.7% (or 0.4% excluding Natal) below the 81.1 million passengers served in 2023, and 6.2% below the 84.2 million served in 2019. The Company is listed on the New York Stock Exchange where it trades under the ticker “CAAP”. For more information, visit http://investors.corporacionamericaairports.com

Forward Looking Statements

Statements relating to our future plans, projections, events or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “believes,” “continue,” “could,” “potential,” “remain,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to: the Covid-19 impact, delays or unexpected casualties related to construction under our investment plan and master plans, our ability to generate or obtain the requisite capital to fully develop and operate our airports, general economic, political, demographic and business conditions in the geographic markets we serve, decreases in passenger traffic, changes in the fees we may charge under our concession agreements, inflation, depreciation and devaluation of the AR$, EUR, BRL, UYU or the AMD against the U.S. dollar, the early termination, revocation or failure to renew or extend any of our concession agreements, the right of the Argentine Government to buy out the AA2000 Concession Agreement, changes in our investment commitments or our ability to meet our obligations thereunder, existing and future governmental regulations, natural disaster-related losses which may not be fully insurable, terrorism in the international markets we serve, epidemics, pandemics and other public health crises and changes in interest rates or foreign exchange rates. The Company encourages you to review the ‘Cautionary Statement’ and the ‘Risk Factor’ sections of our annual report on Form 20-F for the year ended December 31, 2019 and any of CAAP’s other applicable filings with the Securities and Exchange Commission for additional information concerning factors that could cause those differences.

Investor Relations Contact

Patricio Iñaki Esnaola

Email: [email protected]

Phone: +5411 4899-6716

KEYWORDS: Europe Luxembourg United States North America New York

INDUSTRY KEYWORDS: Transportation Air Transport Travel

MEDIA:

Logo
Logo
Posted on

Allegion Named 2025 Gallup Exceptional Workplace Award Winner

Allegion Named 2025 Gallup Exceptional Workplace Award Winner

Honor recognizes Allegion’s ‘most engaged workplace culture’ for second consecutive year

DUBLIN–(BUSINESS WIRE)–Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, has received the 2025 Gallup Exceptional Workplace Award (GEWA) for the second consecutive year. This award recognizes the most engaged workplace cultures in the world — organizations that achieve more by helping their employees focus on what they do best.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319198272/en/

Gallup Exceptional Workplace Award: 2025 Engagement + Strengths Winner

Gallup Exceptional Workplace Award: 2025 Engagement + Strengths Winner

Gallup found that Allegion, through an emphasis on and investment in strengths, continued to engage and develop its people in innovative ways, setting new benchmarks for workplace excellence.

“Congratulations to this year’s Gallup Exceptional Workplace Award winners for setting the standard for a thriving workplace. Your commitment to creating an environment where employees feel valued, heard and empowered to do their best work is truly remarkable. By prioritizing both people and performance, you are shaping the future of work and proving that exceptional workplaces drive real results,” said Jon Clifton, Gallup CEO.

“At Allegion, we believe a strengths-based culture of engagement is an integral part of our company’s foundation,” said Jen Hawes, Allegion senior vice president and chief human resources officer. “When employees are empowered to leverage their unique talents and feel truly connected to our mission, we create an environment where innovation thrives, collaboration deepens and everyone can do their best work.”

“Our team of highly engaged experts are a key differentiator for our company. They solve complex problems and deliver exceptional results for our customers,” added John H. Stone, Allegion president and CEO. “I’m proud of our people, our values and the commitments we hold to employee engagement and strengths development.”

Gallup’s meta-analysis on team engagement and performance is the most comprehensive workplace study ever conducted, with data on more than 3.3 million employees in 347 organizations across 53 industries and 90 countries. Highly engaged organizations significantly outperform their peers on important business outcomes, including customer ratings, profitability, productivity, turnover, safety incidents, shrinkage, absenteeism, quality, wellbeing and organizational citizenship.

For a complete list of GEWA winners, visit the 2025 Gallup Exceptional Workplace Award Winners page. Learn more about the awards here.

About Allegion

At Allegion (NYSE: ALLE), we design and manufacture innovative security and access solutions that help keep people safe where they live, learn, work and connect. We’re pioneering safety with our strong legacy of leading brands like CISA®, Interflex®, LCN®, Schlage®, SimonsVoss® and Von Duprin®. Our comprehensive portfolio of hardware, software and electronic solutions is sold around the world and spans residential and commercial locks, door closer and exit devices, steel doors and frames, access control and workforce productivity systems. Allegion had $3.8 billion in revenue in 2024. For more, visit www.allegion.com.

Media Contact:

Whitney Moorman – Director, Global Communications

317-810-3241

[email protected]

Analyst Contact:

Jobi Coyle – Director, Investor Relations

317-810-3107

[email protected]

Josh Pokrzywinski – Vice President, Investor Relations

463-210-8595

[email protected]

KEYWORDS: Europe Ireland United States North America Indiana

INDUSTRY KEYWORDS: Technology Communications Office Products Home Goods Retail Other Professional Services Finance Interior Design Architecture Professional Services Philanthropy Building Systems Security Fund Raising Foundation Other Manufacturing Residential Building & Real Estate Commercial Building & Real Estate Hardware Construction & Property Manufacturing Consumer Electronics Public Relations/Investor Relations

MEDIA:

Photo
Photo
Gallup Exceptional Workplace Award: 2025 Engagement + Strengths Winner
Logo
Logo
Posted on

Lineage, Inc. Declares Dividend for First Quarter 2025

Lineage, Inc. Declares Dividend for First Quarter 2025

NOVI, Mich.–(BUSINESS WIRE)–
Lineage, Inc. (NASDAQ: LINE) (the “Company”), the world’s largest global temperature-controlled warehouse REIT, today announced that its Board of Directors has declared a cash dividend of $0.5275 per share for the first quarter of 2025. The dividend will be paid on April 21, 2025, to shareholders of record of the Company’s common stock as of the close of business on March 31, 2025.

About Lineage

Lineage, Inc. (NASDAQ: LINE) is the world’s largest global temperature-controlled warehouse REIT with a network of over 485 strategically located facilities totaling approximately 86 million square feet and approximately 3.1 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at onelineage.com and join us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Lineage intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements can generally be identified by Lineage’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “seek,” “objective,” “goal,” “strategy,” “plan,” “focus,” “priority,” “should,” “could,” “potential,” “possible,” “look forward,” “optimistic,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to certain risks and uncertainties, including known and unknown risks, which could cause actual results to differ materially from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of Lineage’s performance in future periods. Except as required by law, Lineage does not undertake any obligation to update or revise any forward-looking statements contained in this release.

Investor Relations Contact

Evan Barbosa

VP, Investor Relations

[email protected]

Media Contact

Megan Hendricksen

VP, Global Marketing & Communications

[email protected]

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Supply Chain Management Retail Communications Construction & Property REIT Public Relations/Investor Relations

MEDIA:

Logo
Logo
Posted on

Redfin Report: America’s Renter Population Grew 1% in the Fourth Quarter

Redfin Report: America’s Renter Population Grew 1% in the Fourth Quarter

New York and Los Angeles are the only metro areas where the majority of households rent. Renting is least common in Cape Coral, FL and Dayton, OH.

SEATTLE–(BUSINESS WIRE)–
(NASDAQ: RDFN) —The number of renter households in America increased 0.8% year over year to 45.4 million in the fourth quarter—the slowest growth since the first quarter of 2023, according to a new report from Redfin (redfin.com), the technology-powered real estate brokerage. The number of homeowner households rose 0.8% to 86.9 million—a growth rate that’s little changed from recent quarters.

That marks the first time in over a year that the number of renter and homeowner households are increasing at the same rate. Prior to this, the number of renter households had been growing faster for four-straight quarters.

Home prices are more than 40% above pre-pandemic levels, while rent prices are roughly 20% above pre-pandemic levels. This is one reason why the rentership rate has recently been rising faster than the homeownership rate. The rental market has seen an influx of supply over the last few years, helping to keep rent growth at bay.

“Owning a home used to be the crux of the American dream, and while many still consider it a rite of passage, a lot of people are opting to rent for longer because they can’t afford to buy a place of their own,” said Redfin Chief Economist Daryl Fairweather. “Even people who can afford to buy homes are choosing leases over mortgages, often because they want a flexible, low-maintenance lifestyle, or want to invest their money somewhere other than real estate. Affluent renters have become more common in nearly three-quarters of major metros since 2019.”

There Are Only Two Metros Where Renters Are the Majority

Just over one-third (34.3%) of U.S. households rent, while nearly two-thirds (65.7%) own—rates that have remained pretty steady over time. But the rentership rate is much higher in pricey coastal metros.

In New York, 51.9% of households rented in the fourth quarter—the highest share among the 75 largest U.S. metropolitan areas. Next came Los Angeles (51.5%), Albany, NY (48.4%), Fresno, CA (48.3%) and San Francisco (46.2%).

Rentership rates tend to be highest in places where it’s expensive to buy a home. All but two of the aforementioned metros (Fresno and Albany—the New York state capitol) have median home sale prices above the national level. A recent Redfin report found that pricey coastal markets have the highest share of wealthy renters.

Renting is least common in places with relatively low home sale prices. In Cape Coral, FL, 15.5% of households rent—the lowest share among the metros Redfin analyzed. It’s followed by Dayton, OH (21.2%), Toledo, OH (21.9%), Columbia, SC (22%) and North Port, FL (22.3%).

This is based on a Redfin analysis of U.S. Census Bureau data going back to 1994. A renter household is defined as one where the head of the household reports to the Census that they are renting out the property, while a homeowner household is one where the head of household reports they own the property. The number of homeowner and renter households have been hovering near record highs because the U.S. population is at a record high.

To view the full report, including charts and metro-level data, please visit: https://www.redfin.com/news/rentership-rate-q4-2024

About Redfin

Redfin (www.redfin.com) is a technology-powered real estate company. We help people find a place to live with brokerage, rentals, lending, and title insurance services. We run the country’s #1 real estate brokerage site. Our customers can save thousands in fees while working with a top agent. Our home-buying customers see homes first with on-demand tours, and our lending and title services help them close quickly. Our rentals business empowers millions nationwide to find apartments and houses for rent. Since launching in 2006, we’ve saved customers more than $1.8 billion in commissions. We serve approximately 100 markets across the U.S. and Canada and employ over 4,000 people.

Redfin’s subsidiaries and affiliated brands include: Bay Equity Home Loans®, Rent.™, Apartment Guide®, Title Forward® and WalkScore®.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

Contact Redfin

Redfin Journalist Services:

Kenneth Applewhaite

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Professional Services Technology Residential Building & Real Estate Insurance Construction & Property Internet

MEDIA:

Logo
Logo
Posted on

Nine UBS Advisors in the South Atlantic Wealth Management Market Named to the Barron’s Top 1200 Financial Advisors List

Nine UBS Advisors in the South Atlantic Wealth Management Market Named to the Barron’s Top 1200 Financial Advisors List

WASHINGTON–(BUSINESS WIRE)–
UBS today announced that nine advisors in the firm’s South Atlantic Wealth Management Market have been named to the Barron’s Top 1200 Financial Advisors list for 2025.

The South Atlantic Wealth Management Market is led by Market Executive Jake Shine and is part of the firm’s Southeast Region, which is led by Regional Director Julie Fox.

“This national recognition is a testament to the hard work and dedication that each of these advisors embody on a daily basis. We congratulate them for this significant industry achievement,” said Jake Shine, South Atlantic Market Executive at UBS.

Among those recognized, UBS advisors Greg Cash and Mitchell Wickham of Wickham Cash Partners ranked No. 1 and No. 2, respectively, in North Carolina.

The advisors named to the list are:

Charlotte, NC:

Greg Cash

Mitchell Wickham

Kevin Moran

Juan Sandoval

Greenville, SC:

Bert Arrowood

W. Clark Gallivan

Raleigh, NC:

Michael Lappin

Bill Smith

Richmond, VA:

Scott Garnett

The 2025 Barron’s Top 1200 Financial Advisors list is compiled based on a variety of criteria including revenue produced for their firm, assets under management, quality of practice, and regulatory record, among other factors.

For the full list and further information, visit: https://www.barrons.com/advisor/report/top-financial-advisors/1000

Notes to Editors

About UBS

UBS is a leading and truly global wealth manager and the leading universal bank in Switzerland. It also provides diversified asset management solutions and focused investment banking capabilities. With the acquisition of Credit Suisse, UBS manages 5.7 trillion dollars of invested assets as per fourth quarter 2023. UBS helps clients achieve their financial goals through personalized advice, solutions and products. Headquartered in Zurich, Switzerland, the firm is operating in more than 50 markets around the globe. UBS Group shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).

https://www.ubs.com

© UBS 2025. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. Past performance is not an indication of future results. For press use only.

Media Contact:

Scott Gamm

Strategy Voice Associates

[email protected]

KEYWORDS: United States North America District of Columbia

INDUSTRY KEYWORDS: Finance Consulting Banking Professional Services Asset Management

MEDIA:

Logo
Logo
Posted on

Lincoln Financial Announces Plans to Launch Two New Private Market Funds to Expand Its Solutions Platform

Lincoln Financial Announces Plans to Launch Two New Private Market Funds to Expand Its Solutions Platform

The company is partnering with Bain Capital and Partners Group to meet evolving client needs

RADNOR, Pa.–(BUSINESS WIRE)–Lincoln Financial (NYSE: LNC), a leading provider of insurance, annuities, group benefits and retirement solutions, announces its expansion into the rapidly growing private markets industry, partnering with Bain Capital, a leading global private investment firm, and Partners Group, one of the largest firms in the global private markets industry, to launch two new private markets-focused funds. Lincoln expects the new offerings to be available in late 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318068482/en/

Jayson Bronchetti, Lincoln Financial

Jayson Bronchetti, Lincoln Financial

“Powered by industry-leading distribution capabilities, a vast network of strategic partner relationships and a nearly 120-year track record of serving customer needs, Lincoln, in partnership with Bain Capital and Partners Group, is well-positioned to deliver innovative and differentiated investment solutions,” said John Kennedy, executive vice president, Chief Distribution & Brand Officer. “This collaboration is a natural extension of Lincoln’s long-standing partnerships with top-tier asset managers and furthers our ability to provide consultative support for financial professionals to meet the evolving needs of their clients.”

Bain Capital will partner with Lincoln Financial to provide investors access to an evergreen fund offering focused on a globally varied portfolio of private credit investments, including direct lending, asset-based finance, and structured credit. With more than 25 years of multi-asset credit investing experience, Bain Capital will leverage its dynamic approach to investing and the deep expertise of its team to source, analyze, and execute compelling opportunities across global debt markets.

Lincoln Financial is partnering with Partners Group to launch an evergreen fund that will provide access to a globally varied cross-sector private markets royalty portfolio. Partners Group will follow a relative value approach to invest across both well-established royalty sectors, such as intellectual property assets in the pharmaceutical and entertainment industries, and emerging high-growth sectors like energy transition, sports, and brands. The fund will look to employ a range of structures, including direct purchases of royalties, creating royalties, and lending against royalties.

“Private market investments have been a staple within the portfolios of institutional and high-net-worth investors for decades. However, in recent years, the demand from individual investors has increased as they seek access to the return potential and diversification benefits that private markets can bring to a well-diversified portfolio,” said Jayson Bronchetti, executive vice president, Chief Investment Officer. “The private market investment strategies we have deployed through our multi-manager framework have enabled us to drive value within our own investment portfolio,” Bronchetti added. “We are thrilled to leverage our asset management relationships and investment and fund structure expertise to create private market funds for our customers to invest directly into these strategies with Bain Capital and Partners Group.”

“By combining our deep expertise in private markets with Lincoln’s innovative, expansive distribution platform, we can further expand access to private markets for more investors,” said John Wright, Partner and Global Head of Credit at Bain Capital. “We look forward to partnering with an institution that has spent more than a century building a legacy of trust, financial stewardship, and value creation for its clients.”

“We’re excited to extend our long-standing strategic partnership with Lincoln to bring a new offering to the US private wealth market,” said Nicholas Hegarty, Managing Director and Co-Head of Client Solutions Americas at Partners Group. “Our 20-year plus track record in managing bespoke evergreen solutions and deep expertise in private markets royalties, coupled with Lincoln’s market-leading distribution capabilities, provide strong foundations from which to deliver a very impactful private markets solution.”

Industry veteran Tom Morelli, Investment Distribution, was recently hired to advance Lincoln’s distribution efforts with private market funds and other investment solutions, leveraging Lincoln’s broad set of capabilities and expertise across distribution and investments.

About Lincoln Financial

Lincoln Financial helps people confidently plan for their vision of a successful financial future. As of December 31, 2024, approximately 17 million customers trust our guidance and solutions across four core businesses – annuities, life insurance, group protection, and retirement plan services. As of December 31, 2024, the company has $321 billion in end-of-period account balances, net of reinsurance. Headquartered in Radnor, Pa., Lincoln Financial is the marketing name for Lincoln National Corporation (NYSE: LNC) and its affiliates, including broker-dealer/affiliate Lincoln Financial Distributors, Inc. Learn more at www.lincolnfinancial.com.

About Bain Capital

Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).

About Partners Group

Partners Group is one of the largest firms in the global private markets industry, with around 1,800 professionals and over USD 150 billion in overall assets under management. The firm has investment programs and custom mandates spanning private equity, private credit, infrastructure, real estate, and royalties. With its heritage in Switzerland and its primary presence in the Americas in Colorado, Partners Group is built differently from the rest of the industry. The firm leverages its differentiated culture and its operationally oriented approach to identify attractive investment themes and to transform businesses and assets into market leaders. For more information, please visit http://www.partnersgroup.com.

Registration statements for each of the evergreen funds have been filed with the Securities and Exchange Commission and are available from the EDGAR database on the SEC’s website (www.sec.gov).The information in the registration statements is not complete and may be changed. The securities of neither fund may be sold until its registration statement is effective. An investor should consider the investment objectives, risks, charges and expenses of each fund carefully before investing. This and other information about each fund will be contained in the fund’s final prospectus, which investors should read carefully when available from the EDGAR database on the SEC’s website (www.sec.gov). This communication is not an offer to sell the shares of either fund and is not soliciting an offer to buy the shares of either fund in any state where the offer or sale is not permitted.

Bain Capital and Partners Group are not affiliated with Lincoln Financial.

LCN-7737711-031225

Media

For Lincoln Financial:

Chrissie Dwyer/ Allyson Vento

(856) 520-2105/ (917) 715-6949

[email protected]

For Bain Capital:

Charlyn Lusk / Thomas Conroy

Stanton

[email protected] / [email protected]

(646) 502-3549 / (646) 502-9006

For Partners Group:

Nicole Dean

Prosek

[email protected]

(248) 836-8851

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Finance Consulting Professional Services Asset Management Insurance

MEDIA:

Photo
Photo
Jayson Bronchetti, Lincoln Financial
Photo
Photo
John Kennedy, Lincoln Financial
Logo
Logo
Posted on

Booz Allen Celebrates Albedo’s Historic Clarity-1 Launch

Booz Allen Celebrates Albedo’s Historic Clarity-1 Launch

The first Very Low Earth Orbit (VLEO) satellite marks significant milestone in commercial space innovation

MCLEAN, Va.–(BUSINESS WIRE)–Booz Allen Hamilton (NYSE: BAH) today announced that Booz Allen Ventures portfolio company Albedo has successfully launched Clarity-1, the first commercial satellite to operate in Very Low Earth Orbit (VLEO), marking a significant milestone in commercial space innovation. This achievement comes just over a year after Booz Allen Ventures’ strategic investment in Albedo, demonstrating the rapid acceleration of developing commercial technology to meet critical government needs.

With Clarity-1 now on orbit, Albedo has introduced a breakthrough capability—10 cm visible and 2-meter thermal imagery from VLEO—delivering resolutions previously limited to aircraft and drones. This will further enhance capabilities for Earth observation and national security use cases across government and industry.

“Albedo’s rapid trajectory from investment to launch demonstrates the speed to outcomes that is critical for national security. We are excited to actively bring these capabilities to the U.S. government,” said Brian MacCarthy, managing director of Booz Allen Ventures. “This milestone showcases Booz Allen’s ability to anticipate, build, and invest in advanced technology that truly transforms missions.”

By leveraging VLEO’s unique advantages, Albedo is positioned to contribute to Space Domain Awareness and provide an alternate vantage point to traditional Earth observation methods. With its Strategic Funding Increase (STRATFI) contract from the Air Force Research Laboratory (AFRL), Albedo’s technology is already playing an important role in the U.S. government’s space strategy.

“The launch of Clarity-1 is a pivotal moment for the space industry,” said Chris Bogdan, executive vice president at Booz Allen and leader of the firm’s Space business. “The ability to collect ultra-high-resolution data at a fraction of the cost and timeline of traditional satellites is a transformational shift in space technology. This launch not only showcases Albedo’s ingenuity but also highlights the power of dual-use commercial technology to meet mission-critical needs.”

“Ultra-high-resolution data will be essential for delivering the necessary intelligence and analytics to inform our nation’s decision-making,” said Winston Tri, co-founder and CPO at Albedo. “As Albedo accelerates its vision to provide unparalleled geospatial insights, we look forward to an ongoing partnership with Booz Allen.”

Booz Allen’s investment in Albedo is part of its broader venture capital strategy, which focuses on identifying, investing, and scaling emerging technologies that can rapidly drive mission outcomes for government clients. Through its corporate venture capital arm, Booz Allen has invested in 13 very promising startups to accelerate AI, cyber, and space innovation in support of national security.

As the leading provider of AI and cybersecurity to the federal government, Booz Allen is uniquely positioned to integrate emerging capabilities into the broader national security ecosystem. Booz Allen is committed to advancing the future of space technology by bridging the gap between commercial innovation and government missions.

About Booz Allen Hamilton

Booz Allen is the advanced technology company delivering outcomes with speed for America’s most critical defense, civil, and national security priorities. We build technology solutions using AI, cyber, and other cutting- edge technologies to advance and protect the nation and its citizens. By focusing on outcomes, we enable our people, clients, and their missions to succeed—accelerating the nation to realize our purpose: Empower People to Change the World®.

With global headquarters in McLean, Virginia, our firm employs approximately 35,900 people globally as of December 31, 2024, and had revenue of $10.7 billion for the 12 months ended March 31, 2024. To learn more, visit www.boozallen.com. (NYSE: BAH)

Forward-Looking Statements

Certain statements contained in this release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include statements that do not directly relate to any historical or current fact. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “forecasts,” “expects,” “intends,” “plans,” “anticipates,” “projects,” “outlook,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “preliminary,” or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct.

These forward-looking statements relate to future events or future financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. A number of important factors could cause actual results to differ materially from those contained in or implied by these forward-looking statements, including those factors discussed in Booz Allen’s filings with the Securities and Exchange Commission (SEC), including Booz Allen’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and other filings and reports that may be filed from time to time with the SEC, which can be found at the SEC’s website at www.sec.gov. All forward-looking statements attributable to Booz Allen or persons acting on Booz Allen’s behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BAHPR-CO

Media Relations: Amanda Allison, [email protected]

Investor Relations: [email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Other Defense Contracts Technology White House/Federal Government Defense Other Policy Issues Security Satellite Photography Government Technology Aerospace Public Policy/Government Manufacturing

MEDIA:

Logo
Logo
Posted on

UiPath Offers Complimentary Trial of Automation Cloud Public Sector to Assist U.S. Government Agencies’ Efficiency Initiatives

UiPath Offers Complimentary Trial of Automation Cloud Public Sector to Assist U.S. Government Agencies’ Efficiency Initiatives

NEW YORK–(BUSINESS WIRE)–
UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced a comprehensive Automation Cloud™ Public Sector free trial designed to help government agencies address operational challenges and drive productivity improvements.

Public sector organizations have specific requirements that demand robust, secure, and compliant software solutions. Automation Cloud Public Sector is a cloud-based solution tailored to the specific requirements of public sector organizations in the United States that enables measurable efficiency gains.

“In an era of rapidly changing policy mandates and increasing efficiency requirements, automation has moved beyond a strategic priority to become a necessity,” said Chris Radich, Public Sector Chief Technology Officer at UiPath. “Government agencies handle vast amounts of sensitive data, from citizen records to financial transactions, making data security and privacy paramount. UiPath is a proud strategic partner of public sector organizations and has years of experience building Automation Centers of Excellence. These initiatives have systematically eliminated millions of hours of repetitive work, which saves taxpayer money and allows talented public servants to focus on mission-critical initiatives that directly serve the American people.”

UiPath Automation Cloud Public Sector holds FedRAMP Moderate compliance, adhering to the rigorous security controls mandated by the Federal Risk and Authorization Management Program. This authorization offers public sector agencies a viable and secure method to achieve aggressive efficiency mandates.

The 60-day free trial of Automation Cloud Public Sector provides government leaders in federal, state, or local agencies with access to critical automation solutions such as process mining, AI-powered Document Understanding, unattended and attended robots, low-code apps, and other capabilities. It offers a pragmatic solution to:

  • decrease administrative costs
  • improve spend management and transparency
  • accelerate document processing with out of the box M/L models
  • demonstrate tangible operational improvements

“Government agencies require practical, implementable solutions to meet evolving operational demands. Our trial provides a direct pathway to measurable efficiency gains,” said Dave Melvin, Vice President of Public Sector at UiPath.

Government agencies can visit here to contact UiPath to enroll in the Automation Cloud Public Sector free trial.

In addition, register here for the UiPath on Tour Agentic Automation Summit in Washington, D.C. on April 29. The annual summit, titled “Ushering in the Era of Efficiency”, will feature prominent government leaders discussing how they are transforming their agencies with agents, robots, and people.

About UiPath

UiPath (NYSE: PATH) develops AI technology that mirrors human intelligence with ever-increasing sophistication, transforming how businesses operate, innovate, and compete. The UiPath Platform™ accelerates the shift toward a new era of agentic automation—one where agents, robots, people, and models integrate seamlessly to enable autonomous processes and smarter decision making. With a focus on security, accuracy, and resiliency, UiPath is committed to shaping a world where AI enhances human potential and revolutionizes industries. For more information, visit www.uipath.com.

UiPath Media Contact

UiPath

[email protected]

UiPath Investor Relations Contact

UiPath

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Software Professional Services Robotics Data Management White House/Federal Government Apps/Applications Technology State/Local Artificial Intelligence Security Other Professional Services Public Policy/Government

MEDIA:

Logo
Logo
Posted on

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

LATHAM, N.Y.–(BUSINESS WIRE)–
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company’s cardiovascular business and products.

Fiscal 2025 Third Quarter Financial Results Conference Call

The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Wednesday, April 09, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13752371.

Virtual Cardiovascular Investor Event

AngioDynamics will host a virtual investor event on April 2, 2025 at 9:00am to provide investors a deeper dive into the cardiovascular technology portfolio and strategic vision.

The event will be webcast and can be accessed through the “Investors” section of the AngioDynamics website at www.angiodynamics.com.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Investors:

AngioDynamics, Inc.

Stephen Trowbridge, Executive Vice President & CFO

(518) 795-1408

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Research Medical Devices Health Technology Cardiology Other Health Health Other Science Science Oncology

MEDIA: